Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.
Xiaofeng Lan, Zitao Wu, Chengyu Wang, Guanxi Liu, Muqin Zhang, Weicheng Li, Zhanjie Luo, Junhao Shen, Ziying Chen, Yuping Ning, Yanling Zhou
J Affect Disord February 23, 2026 DOI: 10.1016/j.jad.2026.121488 via PubMed
Summary
AI-generated from the abstractIn a randomized controlled trial, adolescents with major depressive disorder who received repeated esketamine infusions showed changes in multiple peripheral inflammatory markers compared to those who received a placebo. The treatment was associated with reductions in certain inflammatory markers, suggesting that esketamine may influence immune system activity in this population. The findings indicate a potential link between the antidepressant effects of esketamine and its impact on inflammation, though the exact relationship requires further investigation.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adolescents with major depressive disorder |
| Intervention | Esketamine |
| Key finding | Repeated esketamine infusions were associated with changes in peripheral inflammatory markers in adolescents with major depressive disorder. |
Abstract
Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.